- CytoSorbents (NASDAQ:CTSO) said it has entered into a new $20 million credit facility with Avenue Capital.
- The proceeds are expected to provide non-dilutive working capital to support the company’s ongoing global CytoSorb franchise in critical care and cardiac surgery.
- The agreement has an initial term of three years, provides up to $20 million in total term loan capital, including an initial tranche of $15 million.
2024-07-02